消癌平联合CPT-11化疗方案治疗老年晚期胃癌的临床疗效观察

目的:对消癌平联合CPT-11 化疗治疗老年晚期胃癌的临床疗效和安全性进行观察.方法:选取2013年3月至2015年3月在我院接受治疗的120例老年晚期胃癌患者,随机分为观察组和对照组,每组各60例. 两组患者均采用伊立替康( CPT-11)化疗方案,而观察组在此基础上给予消癌平注射液进行抗肿瘤中药治疗,连用14d为一个周期,两组患者均持续治疗4个周期. 观察比较两组患者的肿瘤标志物水平、近期疗效、远期疗效及不良反应发生率. 结果:经过化疗后两组患者的血清癌胚抗原(CEA)、糖类抗原199(CA199)和糖类抗原242(CA242)水平均显著低于治疗前(P<0. 05);观察组治疗后的CEA、CA199 和CA242 水平显著低于对照组( P<0.05). 观察组的疾病控制率(disease control rate,DCR)为85.0%,显著高于对照组61.7%(P<0.01). 观察组PFS平均PFS(11.57± 2.09)个月显著长于单药组(9.31±0.62)个月(P<0.05). 观察组化疗期间的白细胞减少、谷丙转氨酶升高、腹泻、口腔黏膜炎和手足综合征发生率显著低于单药组( P<0.05). 结论:消癌平注射液联合伊立替康化疗治疗晚期胃癌效果明显,不良反应发生率低,在临床上值得推广应用.

Clinical Efficacy of Xiaoaiping Combined with CPT-11 in the Treatment of Elderly Patients with Advanced Gastric Cancer

Objective:To observe the efficacy and security of Xiaoaiping injection combined with CPT-11 chemotherapy for elderly patients with advanced gastric cancer. Method:120 patients with advanced gas- tric cancer in our hospital from March 2013 to March 2015 were randomly divided into observation group and control group, 60 cases in each group. Both groups received irinotecan ( CPT-11) chemotherapy regimens, while based on the above treatment the observation group was given the additional treatment of Xiaoaiping in-jection of anti-tumor traditional Chinese medicine. Both groups were treated for four consecutive treatment cycles and each cycle contained 14 days. The tumor markers, short-term effect, long-term efficacy and inci-dence of adverse reactions were compared in the two groups. Result:The CEA, CA199 and CA242 levels in both groups were significantly lower after treatment ( P <0.05) . The CEA, CA199 and CA242 levels in the observation group after treatment were significantly lower than those in the control group (P <0.05). The DCR of the observation group was 85.0%, which was significantly higher than that of the control group ( P <0.01). The mean PFS of the observation group was (11.57±2.09) months, which was significantly longer than that of control group ( P<0.05) . The levels of leukopenia, increased alanine aminotransferase, diarrhe-a, stomatitis and hand-foot syndrome in the observation group were significantly lower than those in the monotherapy group ( P <0.05) . Conclusion:Xiaoaiping injection combined with irinotecan chemotherapy for the treatment of advanced gastric cancer has an obvious effect and a low incidence of adverse reactions, which is worthy of clinical application.